News | April 24, 2008

Everolimus DES Improves Outcomes for CAD Patients

April 25, 2008 - An everolimus-eluting stent compared with a paclitaxel-eluting stent resulted in reduced angiographic late loss, noninferior rates of target vessel failure, and fewer major adverse cardiac events during one-year of follow-up in a recent study published in JAMA.

Gregg W. Stone, M.D. (Columbia University Medical Center and the Cardiovascular Research Foundation, New York) and colleagues aimed to evaluate the safety and efficacy of an everolimus-eluting stent compared with a widely used paclitaxel-eluting stent.

To compare everolimus-releasing stents with paclitaxel-releasing stent, Stone and colleagues conducted the SPIRIT III trial using a sample of 1,002 patients with coronary artery disease. During randomization, 669 patients received the everolimus-releasing stent and 333 received the paclitaxel-releasing stent. After 8 months, 436 of 564 patients who were scheduled for an angiographic follow-up completed it, and clinical follow-ups occurred after 1, 6, 9, and 12 months.

Results showed that restenosis as measured by angiography was significantly lowered in the group receiving the everolimus-releasing stent compared to the paclitaxel group. After 9 months, 7.2 percent of patients receiving everolimus stents compared to 9.0 percent receiving paclitaxel stents demonstrated target vessel failure. The risk of major adverse cardiac events (cardiac death, heart attack, or target vessel revascularization) at nine months was reduced by 44 percent in patients receiving the everolimus stent compared with the paclitaxel stent. After one year, this reduction in risk was 42 percent, and it can be explained by fewer heart attacks and target lesion revascularization procedures for patients receiving everolimus.

"This large-scale, prospective, randomized, single-blind, controlled study demonstrates that an everolimus-eluting stent compared with a widely used paclitaxel-eluting stent results in a significant reduction in angiographic in-segment late loss at eight months, with noninferior nine-month rates of ischemia-driven target vessel failure," said the researchers.

Manesh R. Patel, M.D. (Duke University, Durham, N.C.) and David R. Holmes, Jr., M.D. (Mayo Clinic, Rochester, Minn.), in an accompanying editorial, believe that the results found by Stone and colleagues are optimistic.

"These data are encouraging and would qualify as demonstrating biological plausibility and mechanistic effect at the level of a phase 2 study," they said. "What happens next with the everolimus-eluting stent is critical. The current data from the SPIRIT III trial are analogous to the initial comparisons of drug-eluting versus bare-metal stents. Restenosis is reduced with the everolimus stent, potentially with a clinical reduction in target lesion revascularization and myocardial infarction [heart attack]. The clinical effect in a broad population of patients who may be clinically exposed following device approval is unknown. Furthermore, clinical efficacy without any mandated angiographic analysis and long-term safety remain important unanswered clinical issues. Postmarketing approval registries, although complex and expensive to perform optimally, may not address both these concerns."

Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
Gregg W. Stone; Mark Midei; William Newman; Mark Sanz; James B. Hermiller; Jerome Williams; Naim Farhat; Kenneth W. Mahaffey; Donald E. Cutlip; Peter J. Fitzgerald; Poornima Sood; Xiaolu Su; Alexandra J. Lansky; for the SPIRIT III Investigators
JAMA (2008). 299[16]: 1903-1913.

For more information: http://jama.ama-assn.org/cgi/content/short/299/16/1903

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init